For patients hospitalized with community-acquired pneumonia, shortening antibiotic therapy by 5 days does not affect cure rates, a trial published in The Lancet found. The shorter course could substantially reduce antibiotic consumption and resistance, adverse events, and costs.
The phase 2 noninferiority trial conducted in 16 hospitals in France included 310 adult patients with moderately severe community-acquired pneumonia who were clinically stable after 3 days of treatment with β-lactam therapy. The patients were randomly assigned to receive an additional 5 days of β-lactam therapy, consisting of 1 g of oral amoxicillin plus 125 mg of clavulanate 3 times a day, or placebo.
Slomski A. Shorter Antibiotic Therapy Safe for Inpatients With Pneumonia. JAMA. 2021;325(20):2039. doi:10.1001/jama.2021.7721
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: